115 related articles for article (PubMed ID: 19460062)
1. Off-label use of rituximab in a tertiary Queensland hospital.
Butterly SJ; Pillans P; Horn B; Miles R; Sturtevant J
Intern Med J; 2010 Jun; 40(6):443-52. PubMed ID: 19460062
[TBL] [Abstract][Full Text] [Related]
2. Experience with low-dose rituximab in off-label indications at two tertiary hospitals.
Chay J; Donovan P; Cummins L; Kubler P; Pillans P
Intern Med J; 2013 Aug; 43(8):871-82. PubMed ID: 23919335
[TBL] [Abstract][Full Text] [Related]
3. Prospective data collection of off-label use of rituximab in Australian public hospitals.
O'Connor K; Liddle C
Intern Med J; 2013 Aug; 43(8):863-70. PubMed ID: 23735074
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in the treatment of bullous systemic lupus erythematosus.
Alsanafi S; Kovarik C; Mermelstein AL; Werth VP
J Clin Rheumatol; 2011 Apr; 17(3):142-4. PubMed ID: 21441817
[TBL] [Abstract][Full Text] [Related]
5. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma.
Horvat M; Kloboves Prevodnik V; Lavrencak J; Jezersek Novakovic B
Oncol Rep; 2010 Oct; 24(4):1101-7. PubMed ID: 20811695
[TBL] [Abstract][Full Text] [Related]
6. Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity.
Kormelink TG; Tekstra J; Thurlings RM; Boumans MH; Vos K; Tak PP; Bijlsma JW; Lafeber FP; Redegeld FA; van Roon JA
Ann Rheum Dis; 2010 Dec; 69(12):2137-44. PubMed ID: 20679475
[TBL] [Abstract][Full Text] [Related]
7. Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008-2016.
Wongseelashote S; Tayal V; Bourke PF
Intern Med J; 2018 Feb; 48(2):165-172. PubMed ID: 28742259
[TBL] [Abstract][Full Text] [Related]
8. Off-label use of rituximab in systemic rheumatic diseases: case series and review.
Araújo F; Silva I; Sepriano A; Nero P; Branco JC
Acta Reumatol Port; 2013; 38(4):290-4. PubMed ID: 24435034
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in critically ill patients.
Dimopoulos G; Armaganidis A; Poulakou G; Matthaiou DK
Minerva Anestesiol; 2013 Feb; 79(2):185-93. PubMed ID: 23135691
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for primary cutaneous diffuse large B-cell lymphoma-leg type.
Fenot M; Quereux G; Brocard A; Renaut JJ; Dreno B
Eur J Dermatol; 2010; 20(6):753-7. PubMed ID: 20956100
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial.
Tak PP; Rigby WF; Rubbert-Roth A; Peterfy CG; van Vollenhoven RF; Stohl W; Hessey E; Chen A; Tyrrell H; Shaw TM;
Ann Rheum Dis; 2011 Jan; 70(1):39-46. PubMed ID: 20937671
[TBL] [Abstract][Full Text] [Related]
12. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).
Nishida M; Usuda S; Okabe M; Miyakoda H; Komatsu M; Hanaoka H; Teshigawara K; Niwa O
Int J Oncol; 2007 Jul; 31(1):29-40. PubMed ID: 17549402
[TBL] [Abstract][Full Text] [Related]
13. Rituximab for severe myasthenia gravis--experience from five patients.
Lindberg C; Bokarewa M
Acta Neurol Scand; 2010 Oct; 122(4):225-8. PubMed ID: 20199513
[TBL] [Abstract][Full Text] [Related]
14. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus.
Catapano F; Chaudhry AN; Jones RB; Smith KG; Jayne DW
Nephrol Dial Transplant; 2010 Nov; 25(11):3586-92. PubMed ID: 20466686
[TBL] [Abstract][Full Text] [Related]
17. Innovative uses of rituximab in dermatology.
Carr DR; Heffernan MP
Dermatol Clin; 2010 Jul; 28(3):547-57. PubMed ID: 20510764
[TBL] [Abstract][Full Text] [Related]
18. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
Smith MR
Oncogene; 2003 Oct; 22(47):7359-68. PubMed ID: 14576843
[TBL] [Abstract][Full Text] [Related]
19. Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%.
Mohamedbhai SG; Sibson K; Marafioti T; Kayani I; Lowry L; Goldstone AH; Linch DC; Ardeshna KM
Br J Haematol; 2011 Jan; 152(2):175-81. PubMed ID: 21092025
[TBL] [Abstract][Full Text] [Related]
20. Modulation of CD20 antigen expression after rituximab treatment: a retrospective study in patients with chronic lymphocytic leukemia.
D'Auria F; Guariglia R; Villani O; Mansueto G; Grieco V; Zonno A; Bianchino G; Di Giovannantonio L; Vita G; Musto P
Clin Ther; 2010 Oct; 32(11):1911-6. PubMed ID: 21095486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]